LMO2 is an intrinsically disordered transcription factor activated in T cell leukaemia that is difficult to target. It forms part of a multiprotein complex that has bipartite DNA binding through ...

As leaders look to design the laboratory of the future, the ones that enable agility, flexibility and sustainability will be ...

Researchers at Fred Hutch Cancer Center invented a new screening method called ReLiC that uses CRISPR-Cas9 to test all the ...

Q2 2025 Earnings Call Transcript August 4, 2025 Syndax Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0 ...

The Uppsala University spinout aims to use its SuperRCA mutation detection technology for applications including molecular residual disease monitoring.

When the patient opted against surveillance CT scans and a follow-up PET scan, her physician ordered the CyPath® Lung test in March 2025. The test result of 0.56 – classified as “likely malignancy” – ...